Treatment of diabetes with synthetic beta cells

Details Treatment of diabetes with synthetic beta cells Treatment of diabetes with synthetic beta cells

2005-05-12

2008-09-16

Li, Q. Janice (Department: 1633)

Chemistry: molecular biology and microbiology

Vector, per se

C424S093200, C424S093210, C536S023500, C536S024100

Reexamination Certificate

active

07425443

ABSTRACT:
Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

REFERENCES:
Robbins et al, Pharmacol Ther 1998;80:35-47.
Jeffe et al, Nat Genet 1992;1:372-8.
Verma et al, Nature 1997;389;239-42.
Freeman et al, Intl J Mol Med 1999; 4:585-592.
Miller et al, 1995, FASEB J., vol. 9, pp. 190-199.
Orkin et al. NIH Report, Dec. 1995.
Peterson, Statement of Amy Patterson M.D., Feb. 2000.
Levine et al, Mol Med Today Apr. 1999;5:165-171.
Ludwig et al, Curr Opin Organ Transplant 2006;11:94-100.
Han B & Zhang J, “Regulation of gene expression by internal ribosome entry sites or cryptic promoters: the elF4G story,” Mol. Cell. Biol. 22:7372-7384 (2002).
Han B, et al., “Tight control of platelet-derived growth factor B/c-sis expression by interplay between the 5′-untranslated region sequence and the major upstream promoter,” J. Biol. Chem. 278:46983-46993 (2003).
Pedersen S, et al., “Human insulin-like growth factor II leader 2 mediates internal initiation of translation,” Biochem. J. 363:37-44 (2002).
Yang Q & Sarnow P, “Location of the internal ribosome entry site in the 5′ non-coding region of the immunoglobulin heavy-chain binding protein (BiP) mRNA: evidence for specific RNA-protein interactions,” Nucleic Acids Res. 25:2800-2807 (1997).

Affiliated with

Also associated with

Rating

Treatment of diabetes with synthetic beta cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of diabetes with synthetic beta cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes with synthetic beta cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3990727